---
title: "Understanding the Market | TRANSTHERA-B rises over 15% again, total market value surpasses HKD 40 billion, and the Phase II clinical trial for Engeletinib is approved to proceed"
description: "TRANSTHERA-B rose over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it rose 11.11%, trading at HKD 100, with a transaction volume of HKD 148 m"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256837391.md"
published_at: "2025-09-11T02:53:04.000Z"
---

# Understanding the Market | TRANSTHERA-B rises over 15% again, total market value surpasses HKD 40 billion, and the Phase II clinical trial for Engeletinib is approved to proceed

> TRANSTHERA-B rose over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it rose 11.11%, trading at HKD 100, with a transaction volume of HKD 148 million. In terms of news, TRANSTHERA announced that its core product, TT-00420, in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer that has failed previous treatments. The clinical treatment strategy of combining TT-00420 with Fulvestrant may bring new breakthroughs in the treatment of breast cancer patients. In addition, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Guoyuan International stated that the company is a leader in R&D within its niche industry, and TT-00420 is the world's first and only FGFR inhibitor to enter the registration clinical stage for the treatment of recurrent or refractory cholangiocarcinoma patients. It is also the world's first investigational drug that may simultaneously inhibit the FGFR/JAK pathway and has clinical efficacy evidence targeting metastatic castration-resistant prostate cancer

According to Zhitong Finance APP, TRANSTHERA-B (02617) has risen over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it has increased by 11.11%, trading at HKD 100, with a transaction volume of HKD 148 million.

In terms of news, TRANSTHERA announced that its core product, TT-00420, in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer that has failed previous treatments. The clinical treatment strategy of TT-00420 combined with Fulvestrant may bring new breakthroughs in the treatment of breast cancer patients.

Additionally, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Guoyuan International stated that the company is a leader in research and development in its niche industry, and TT-00420 is the world's first and only FGFR inhibitor to enter the registration clinical stage for the treatment of recurrent or refractory cholangiocarcinoma patients. It is also the world's first research drug that may simultaneously inhibit the FGFR/JAK pathway and has clinical efficacy evidence targeting metastatic castration-resistant prostate cancer

### Related Stocks

- [02617.HK - TRANSTHERA-B](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 港股異動：基石投資者解禁引發擔憂，藥捷安康-B 股價暴跌 16.36% | 藥捷安康-B 跌 16.36%；信達生物漲 0.92%，成交額達到 2.51 億港幣；三生製藥漲 1.68%，成交額達到 1.83 億港幣；榮昌生物漲 0.92%，成交額達到 1.37 億港幣；百濟神州漲 0.43%，市值達到 2889 億 | [Link](https://longbridge.com/en/news/270561769.md) |
| 港股異動：藥捷安康-B 漲 16.21%，資金流向活躍，板塊趨勢引發市場關注？ | 藥捷安康-B 漲 16.21%；三生製藥跌 1.44%，成交額達到 1.3 億港幣；信達生物跌 1.01%，成交額達到 1.17 億港幣；康方生物跌 1.52%，成交額達到 70.04 百萬港幣；百濟神州跌 1.14%，市值達到 2799  | [Link](https://longbridge.com/en/news/271050704.md) |
| 翰森製藥的關鍵肺癌藥物奧莫替尼獲得歐盟批准 | 翰森製藥獲得歐盟對關鍵肺癌藥物阿莫雷替尼的批准 | [Link](https://longbridge.com/en/news/276393466.md) |
| Cornerstone Advisors LLC 減少了其在 Trane Technologies plc $TT 的股份 | Cornerstone Advisors LLC 在第三季度減少了對 Trane Technologies plc (NYSE:TT) 的持股比例，下降了 28.7%，目前持有 7,200 股，價值 3,038,000 美元。其他機構投資者 | [Link](https://longbridge.com/en/news/276340149.md) |
| 加拿大宣佈新國防工業戰略，注重國內製造以重獲戰備能力 | 加拿大總理卡尼於 2 月 17 日宣佈新的國防工業戰略，設定未來十年目標，包括將 70% 的國防合同授予本國企業，旨在實現國內採購和維護大部分軍事裝備。 | [Link](https://longbridge.com/en/news/276178964.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.